Cboe UK DKK

Novo Nordisk A/S (NOVOBC.XC)

489.77

0.00

(0.00%)

At close: June 6 at 3:45:57 PM GMT+1

Why Novo Nordisk Stock Eked Out a Win on Monday

A media report stated that an activist investor is accumulating a stake in the Wegovy maker. Wegovy and Ozempic maker Novo Nordisk (NYSE: NVO) saw its stock price tick up slightly on Monday, on a media report about the possible entry of an activist investor. Market players cautiously bid the shares a little more than 1% higher on the news. Citing unnamed "people with knowledge of the details," the Financial Times reported Monday that London-based activist hedge fund Parvus Asset Management is accumulating stock in Novo Nordisk.

Motley Fool 1 hour ago

NVO
Obesity Newcomer Metsera Enters The Ring With A Punch — And A Big Stock Jump

Metsera stock surged Monday after the drugmaker unveiled "solid" results for a potential monthly shot to stoke weight loss.

Investor's Business Daily 3 hours ago

MTSR

NONOF

NVO
Sector Update: Health Care Stocks Mixed

Health care stocks ended mixed Monday with the NYSE Health Care Index adding 0.2% and the Health Car

PREMIUM
MT Newswires 4 hours ago

UNH

NVO
Market Chatter: Novo Nordisk Faces Pressure From Parvus Over CEO Search

Novo Nordisk (NVO) is facing pressure from activist hedge fund Parvus Asset Management, which is bui

PREMIUM
MT Newswires 6 hours ago

NVO
The Zacks Analyst Blog Highlights Oracle, Novo Nordisk, Linde, NVE and CPS Technologies

Zacks spotlights ORCL, NVO, LIN, NVEC and CPSH for their strategic growth plays, from AI cloud to medtech sensing and advanced materials.

Zacks 8 hours ago

NVO

ORCL

NVEC
Eli Lilly's Obesity Drug Success Spurs Japanese Biotech's Anti-Muscle-Wasting Combo Therapy

Chugai Pharmaceutical Co. Ltd. (OTC:CHGCY) believes its anti-muscle-wasting drug could be used alongside Eli Lilly And Co.’s (NYSE:LLY) oral obesity pill, orforglipron. Roche Holdings AG (OTC:RHHBY) is a major shareholder of Chugai, a Japanese pharmaceutical company. The company’s optimism stems from growing evidence that modern weight-loss drugs can lead to significant muscle loss, an issue Chugai thinks it can help address. Hitoshi Iikura, a senior executive at Chugai, told the Financial Times

Benzinga 11 hours ago

LLY

ROG.SW

NVO
The biggest obesity deals of 2025 so far

Three pharma giants are snapping up new assets to find stronger footing in the quickly shifting weight loss market.

Pharma Voice 16 hours ago

ROG.SW

LLY

NVO
Challenges pharma companies face in push into US manufacturing

Yahoo Finance senior health reporter Anjalee Khemlani explains the pharmaceutical industry's push into domestic manufacturing in the US, as a reshoring tactic to tighten up the supply chain. Planning can still take several years to be finalized and face cost barriers amid tariffs. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.

Yahoo Finance Video 3 days ago

SNY

SNYNF

LLY
The Next Look At Amgen's Obesity Drug Is Coming. Here's What Investors Are Watching.

Later this month, the Street will have a fresh opportunity to gauge the potential for Amgen's experimental weight-loss drug, MariTide.

Investor's Business Daily 3 days ago

NONOF

NVO

AMGN
Top Research Reports for Oracle, Novo Nordisk & Linde

ORCL gains on strong cloud momentum, while NVO battles obesity headwinds and LIN leans on $10B backlog for growth.

Zacks 3 days ago

NVO

ORCL

NVEC
Is Novo Nordisk's Next Generation Obesity Pipeline a Game Changer?

NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.

Zacks 3 days ago

NVO

LLY
Novo Nordisk's Wegovy Tied To Increased Risk Of Rare Vision-Loss Disorder, European Regulators Say

The European Medicines Agency's (EMA) safety committee (PRAC) has concluded its review of medicines containing semaglutide following concerns regarding a possible increased risk of developing non-arteritic anterior ischemic optic neuropathy (NAION), an eye condition that may cause vision loss. Novo Nordisk A/S's (NYSE:NVO) semaglutide, a GLP-1 receptor agonist, is the active substance in certain medicines used for diabetes and obesity (Ozempic, Rybelsus, and Wegovy). After reviewing all availabl

Benzinga 3 days ago

NVO
Was Jim Cramer Right About Novo Nordisk A/S (NVO)?

We recently published a list of Was Jim Cramer Right About These 9 Stocks? In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other stocks that Jim Cramer discusses. In a prior call, a viewer asked about Novo Nordisk A/S (NYSE:NVO) as a long-term growth stock. Cramer […]

Insider Monkey 3 days ago

NVO

LLY
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know

Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.

Zacks 3 days ago

NVO
Novo Nordisk Stock: Is It Still a Smart Buy?

This one-time weight-loss drug leader has suffered several setbacks lately. It isn't wise to count out this veteran pharmaceutical company, however. Much like the long-term users of its most popular product, Novo Nordisk's (NYSE: NVO) stock has slimmed down considerably of late.

Motley Fool 3 days ago

NVO

LLY
Should You Invest $1,000 in Eli Lilly today?

Eli Lilly is a pharma player, but it offers the growth of a tech stock thanks to its weight loss drugs portfolio. The weight loss market could represent a multibillion-dollar opportunity well into the next decade. Eli Lilly (NYSE: LLY) sells a broad range of medicines, from cancer and immunology drugs to treatments for migraine.

Motley Fool 4 days ago

LLY

NVO
1 Underrated Reason to Buy This Market-Beating Stock

Eli Lilly recently acquired a smaller biotech for its promising investigational pain medication. The company generates strong sales from products outside of diabetes and obesity care. Eli Lilly's portfolio, both within and outside its core area, makes the stock attractive.

Motley Fool 5 days ago

LLY

NVO
Why Novo Nordisk (NVO) is a Top Dividend Stock for Your Portfolio

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novo Nordisk (NVO) have what it takes? Let's find out.

Zacks 7 days ago

NVO
Weight Loss Drug ETF (THNR) Hits New 52-Week High

THNR hits a 52-week high, fueled by gains in Eli Lilly and Novo Nordisk -- could the rally still have legs?

Zacks 7 days ago

LLY

NVO
Hims to cut 4% of workforce amid ban on weight-loss drug copies

NEW YORK (Reuters) -Telehealth platform Hims & Hers will cut 68 employees, or about 4% of its workforce, as it adjusts to a U.S. ban on manufacturing mass copies of the weight-loss drug Wegovy. A U.S. Food and Drug Administration ban on compounded copies of Wegovy, made by Novo Nordisk, took effect on May 22. Hims did not provide details about the roles that were cut, but said they were implemented across teams.

Reuters 10 days ago

NVO

Performance Overview

Return	NOVOBC.XC	OMX Copenhagen 25 Index (^OMXC25)
AAJ	-21.60%	+1.93%
1-Year	-48.52%	--
3-Year	+33.03%	+8.04%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Novo Nordisk A/S (NOVOBC.XC)

Why Novo Nordisk Stock Eked Out a Win on Monday

Obesity Newcomer Metsera Enters The Ring With A Punch — And A Big Stock Jump

Sector Update: Health Care Stocks Mixed

Market Chatter: Novo Nordisk Faces Pressure From Parvus Over CEO Search

The Zacks Analyst Blog Highlights Oracle, Novo Nordisk, Linde, NVE and CPS Technologies

Eli Lilly's Obesity Drug Success Spurs Japanese Biotech's Anti-Muscle-Wasting Combo Therapy

The biggest obesity deals of 2025 so far

Challenges pharma companies face in push into US manufacturing

The Next Look At Amgen's Obesity Drug Is Coming. Here's What Investors Are Watching.

Top Research Reports for Oracle, Novo Nordisk & Linde

Is Novo Nordisk's Next Generation Obesity Pipeline a Game Changer?

Novo Nordisk's Wegovy Tied To Increased Risk Of Rare Vision-Loss Disorder, European Regulators Say

Was Jim Cramer Right About Novo Nordisk A/S (NVO)?

Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know

Novo Nordisk Stock: Is It Still a Smart Buy?

Should You Invest $1,000 in Eli Lilly today?

1 Underrated Reason to Buy This Market-Beating Stock

Why Novo Nordisk (NVO) is a Top Dividend Stock for Your Portfolio

Weight Loss Drug ETF (THNR) Hits New 52-Week High

Hims to cut 4% of workforce amid ban on weight-loss drug copies

Performance Overview